DELRAY BEACH, Fla.- PositiveID Corporation ("PositiveID" or "Company"), a developer of biological detection and diagnostics solutions, today announced that its Firefly Dx system, designed to deliver molecular diagnostic results rapidly at the point-of-need, which could be used for quick Ebola detection, was featured on the Fox news San Francisco affiliate.

"The best way to prevent the spread of the Ebola virus throughout the

world is to detect it as early and quickly as possible, at the source,

and we believe our Firefly system will give us that ability," stated

William J. Caragol, Chairman and CEO of PositiveID. "We are very proud

of the development, design and intellectual property protection

achieved to date for our Firefly system, designed to deliver rapid

molecular diagnostic testing faster, cheaper and exactly where it's

needed."

About Firefly

PositiveID's Firefly Dx is a point-of-need, handheld system designed to deliver molecular diagnostic results using real-time TaqMan(R) PCR

(polymerase chain reaction) chemistry. Firefly is being developed to

meet the growing need in healthcare and molecular diagnostics markets

for more rapid and accurate point-of-need diagnostics that will enable

hospitals, physicians, military personnel, and others to save lives.

Firefly can derive results from a sample in less than 20 minutes, at

the point of need, compared to two to four hours for a lab device,

which would enable accurate diagnostics leading to more rapid and

effective treatment than what is currently available with existing

systems.

About PositiveID Corporation

PositiveID Corporation is an emerging growth company and developer of

biological detection systems for America's homeland defense industry as well as rapid biological testing. PositiveID is focused on the

development of microfluidic systems for the automated preparation of

and performance of biological assays in order to detect biological

threats at high-value locations, as well as analyze samples in a

medical environment. For more information on PositiveID, please visit

http://www.PositiveIDCorp.com.

Statements about PositiveID's future expectations, including, without

limitation, the likelihood that its Firefly Dx system could be used for quick Ebola detection; the likelihood that the best way to prevent the spread of the Ebola virus throughout the world is to detect it as early and quickly as possible, at the source, and the likelihood that

PositiveID's Firefly system will give the Company that ability; and all statements in this press release constitute "forward-looking

statements" within the meaning of Section 27A of the Securities Act of

1933, Section 21E of the Securities Exchange Act of 1934, and as that

term is defined in the Private Litigation Reform Act of 1995. Such

forward-looking statements involve risks and uncertainties and are

subject to change at any time, and PositiveID's actual results could

differ materially from expected results. These risks and uncertainties

include, without limitation, the Company's ability to target the

bio-threat detection and rapid medical testing sectors; the Company's

ability to raise capital; the Company's ability to complete the

development of its Firefly system; as well as other risks. Additional

information about these and other factors that could affect the

Company's business is set forth in the Company's various filings with

the Securities and Exchange Commission, including those set forth in

the Company's 10-K filed on April 11, 2014, and 10-Qs filed on May 20,

2014, November 19, 2013, and August 14, 2013, as amended August 19,

2013, under the caption "Risk Factors." The Company undertakes no

obligation to update or release any revisions to these forward-looking

statements to reflect events or circumstances after the date of this

statement or to reflect the occurrence of unanticipated events, except

as required by law.